Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase

Area of Science:

• Biochemistry and Molecular Biology
• Medicinal Chemistry
• Cancer Research

Background:

• Human Eyes Absent (EYA) proteins exhibit Tyr phosphatase activity essential for cancer and metastasis.
• Targeting EYA proteins presents a promising strategy for cancer therapy.

Purpose of the Study:

• To characterize and optimize a novel class of allosteric inhibitors targeting EYA2.
• To elucidate the structure-activity relationships and binding modes of these inhibitors.
• To provide tools for exploring EYA2's role in cancer and for structure-based drug discovery.

Main Methods:

• Synthesis and medicinal chemistry optimization of EYA2 inhibitors.
• Biochemical and biophysical assays to assess inhibitor activity and binding.
• Co-crystallization of EYA2 with inhibitors to determine structural interactions.
• Structure-activity relationship (SAR) studies.

Main Results:

• Demonstrated that EYA2 inhibitor binding prevents essential Mg2+ cofactor association.
• Synthesized analogues with improved potency and characterized their structure-activity relationships.
• Obtained two co-crystal structures confirming inhibitor binding modes.
• Provided detailed molecular insights into EYA2-inhibitor interactions.

Conclusions:

• Developed potent allosteric inhibitors of EYA2 that function by allosterically inhibiting Mg2+ binding.
• The characterized inhibitors serve as valuable tools for functional studies and as reference compounds for developing new allosteric phosphatase inhibitors.
• Co-crystal structures provide a foundation for structure-based drug design against EYA2 for cancer therapy.